CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-IncRNA pathway and stabilizing epithelial-mesenchymal transition protein

Chi Hin Wong¹, Ut Kei Lou¹, Frederic Khe-Cheong Fung¹, Joanna H. M. Tong², Chang-hua Zhang³, Ka-Fai To², Stephen Lam Chan⁴ and Yangchao Chen¹,5*

Abstract

Background: Circular RNAs (circRNAs) play important roles in many biological processes. However, the detailed mechanism underlying the critical roles of circRNAs in cancer remains largely unexplored. We aim to explore the molecular mechanisms of circRTN4 with critical roles in pancreatic ductal adenocarcinoma (PDAC).

Methods: CircRTN4 expression level was examined in PDAC primary tumors. The oncogenic roles of circRTN4 in PDAC tumor growth and metastasis were studied in mouse tumor models. Bioinformatics analysis, luciferase assay and miRNA pulldown assay were performed to study the novel circRTN4-miRNA-IncRNA pathway. To identify circRTN4-interacting proteins, we performed circRNA-pulldown and mass spectrometry in PDAC cells. Protein stability assay and 3-Dimensional structure modeling were performed to reveal the role of circRTN4 in stabilizing RAB11FIP1.

Results: CircRTN4 was significantly upregulated in primary tumors from PDAC patients. In vitro and in vivo functional studies revealed that circRTN4 promoted PDAC tumor growth and liver metastasis. Mechanistically, circRTN4 interacted with tumor suppressor miR-497-5p in PDAC cells. CircRTN4 knockdown upregulated miR-497-5p to inhibit the oncogenic IncRNA HOTTIP expression. Furthermore, we identified critical circRTN4-interacting proteins by circRNA-pulldown in PDAC cells. CircRTN4 interacted with important epithelial-mesenchymal transition (EMT)-driver RAB11FIP1 to block its ubiquitination site. We found that circRTN4 knockdown promoted the degradation of RAB11FIP1 by increasing its ubiquitination. Also, circRTN4 knockdown inhibited the expression of RAB11FIP1-regulating EMT-markers Slug, Snai1, Twist, Zeb1 and N-cadherin in PDAC.

Conclusion: The upregulated circRTN4 promotes tumor growth and liver metastasis in PDAC through the novel circRTN4-miR-497-5p-HOTTIP pathway. Also, circRTN4 stabilizes RAB11FIP1 to contribute EMT.

Keywords: circRTN4, Epithelial-mesenchymal transition, HOTTIP, MiRNAs, Pancreatic ductal adenocarcinoma

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer mortality worldwide [1]. Delayed diagnosis and ineffective treatment regimen frequently result in poor prognosis with low overall survival (9%) in PDAC patients [2–4]. Therefore, understanding the mechanism underlying PDAC initiation and progression is crucial for the development of novel diagnostic biomarkers and therapeutic targets.

Circular RNAs (circRNAs) represent a class of non-coding RNAs with the covalently joining of the 3′ end of a transcript to its 5′ end in a circular structure. Emerging studies identified important roles of circRNAs dysregulation in cancer progression [5–7]. Although circRNAs are frequently reported to regulate gene expression through functioning as microRNA (miRNA) sponges [8], many circRNAs have much lower abundance than miRNAs. This indicates that circRNAs may have additional molecular mechanisms in regulating gene expression. Particularly, the detailed functions and critical mechanisms by circRNAs in PDAC are still largely unexplored.

We profiled circRNAs expression in PDAC to identify circRNAs that played important roles in PDAC [9]. One of the upregulated circRNAs was examined in current study. circRTN4 (also named as hsa_circ_0001006), which was derived from the exon 4 and 5 of Reticulon 4 (RTN4) mRNA, was frequently upregulated in PDAC cells and primary tumors. We found that circRTN4 promoted PDAC cell growth, migration, and invasion. Also, in vivo studies demonstrated that circRTN4 promoted tumor growth and liver metastasis. Mechanistically, we identified a novel circRNA-miRNA-long non-coding RNA (lncRNA) pathway in PDAC. CircRTN4 promoted the oncogenic lncRNA HOXA Transcript At The Distal Tip (HOTTIP) expression by sponging miR-497-5p. In additional to regulating lncRNA expression, circRTN4 interacted with RAB11FIP1 to enhance its stability for promoting epithelial-mesenchymal transition (EMT) in PDAC. Collectively, our results demonstrated that circRTN4 played critical roles in PDAC progression through promoting the expression of HOTTIP and enhancing the stability RAB11FIP1 for EMT. Our results broaden the understanding on the roles of circRNAs in regulating gene expression in PDAC.

Methods
Clinical samples and mammalian cell lines
88 pairs of PDAC primary tumor and adjacent non-tumor tissues were obtained from patients who underwent pancreatic resection at the Prince of Wales Hospital, Hong
circRTN4 clone. The efficiency of knockdown was confirmed by qRT-PCR. For tumor growth assay, 6×10^5 CFPAC-1 cells with sh-circRTN4 or shSCR were resuspended in 1× PBS with 20% matrigel and were injected orthotopically to the head of the pancreas of randomized male BALB/c nude mice aged 4 to 6 weeks (four mice per group) [9]. After tumor formation, tumor growth was monitored every 3–4 days, and the tumor volume was measured and calculated by the equation: volume = (Length x width^2) / 2. Finally, mice were sacrificed, and tumors were excised. Tumor weight was measured. Tumor tissues were collected for analysis.

For tumor metastasis assay, 5×10^5 CFPAC-1 cells with sh-circRTN4 or shSCR were resuspended in 1× PBS with 20% matrigel and were injected subcutaneously into the right flank of the randomized male BALB/c nude mice aged 4 to 6 weeks (seven mice per group) [9]. After tumor formation, tumor growth was monitored every 3–4 days, and the tumor volume was measured and calculated by the equation: volume = (Length x width^2) / 2. Finally, mice were sacrificed, and tumors were excised. Tumor weight was measured. Tumor tissues were collected for analysis.

Protein stability assay
Analysis of protein stability was performed using cycloheximide (CHX) (Sigma) [13]. After circRTN4 knockdown in PANC-1 cells for 72h, cells were treated with 100μg/ml CHX for 2, 4 and 8h. The level of RAB11FIP1 and GAPDH at each time-point were analyzed by immunoblotting.

Immunoblotting
The whole cell extract was prepared by lysing cells in RIPA lysis buffer with proteinase inhibitors (Roche, Basel, Switzerland) and phosphatase inhibitor (Thermo Fisher Scientific, Waltham, MA, USA). Proteins were resolved by SDS-PAGE at different percentages, transferred to PVDF membrane and immunoblotted overnight at 4°C with antibodies against HOXA13 (rabbit; ab106503 Abcam, Cambridge, UK; 1:1000); RAB11FIP1 (rabbit; 16,778–1-AP Proteintech, Rosemont, IL, USA; 1:1000); N-cadherin (mouse; 14–3259 eBioscience, Waltham, MA, USA; 1:1000); PARP (rabbit; #9542 Cell Signaling Technology, Danvers, MA, USA; 1:1000); Bcl-2 (rabbit; 04–436 Millipore, Burlington, MA, USA; 1:1000); and GAPDH (rabbit; #5174 Cell Signaling Technology; 1:1000). Chemiluminescent signals were developed using Clarity™ Western ECL Substrate (Bio-Rad, Hercules, CA, USA).

Immunohistochemical staining
Immunohistochemical staining was performed using Histostain-Plus IHC Kit, HRP, broad spectrum (Life Technologies, Carlsbad, CA, USA) [14]. The sections were probed with antibodies against Ki67 (rabbit; NB500–170 Novus Biologicals, Centennial, CO, USA; 1:100); Bcl-2 (rabbit; 04–436 Millipore; 1:100); HOXA13

CircRNA overexpression plasmid was constructed by cloning the RTN4 exon 4 and 5 into pcDNA3.1 (+) circRNA mini vector, which was a gift from Jeremy Wilusz (Addgene plasmid # 60648) [9, 11]. pmiR-circRTN4 reporter plasmid for luciferase assay was constructed by cloning circRTN4 sequence into region directly downstream of the firefly luciferase gene in the pmiR-Reporter (Promega, Madison, WI, USA). Mutation in the miRNA binding site of the pmiR-circRTN4 reporter plasmid and the RAB11FIP1 binding site of the pcDNA3.1 (+)-circRTN4 plasmid were generated using KAPA HiFi DNA Polymerase (KapaBiosystem, St. Louis, MO, USA) and primers with the mutation site. SiRNAs and miRNAs mimics were purchased from GenePharma (Shanghai, China). The sequences were presented in the Supplementary Table 1. Plasmids, siRNAs and miRNAs transfection were performed by Lipofectamine 3000 (Invitrogen, Waltham, MA, USA), according to the manufacturer’s protocol.

Construction of the lentiviral vector for shRNA knockdown and the establishment of stable knockdown CFPAC-1 cell lines were described previously [12]. Briefly, shRNA sequence targeting circRTN4 was cloned into lentiviral transfer vector. The VSV-G-pseudotyped lentivirus was produced by co-transfecting packaging vectors: pCMV-VSVG, pRSV-REV and pMDLg/pRRE with transfer vectors in HEK293T cells. CFAPC-1 cell lines were described previously [12]. Lentiviral production and infection were performed by Lipofectamine 3000 (Invitrogen, Waltham, MA, USA), according to the manufacturer’s protocol.

In vivo PDAC mouse model
For tumor growth assay, 6×10^5 CFPAC-1 cells with sh-circRTN4 or scramble control (shSCR) were resuspended in 1× PBS with 20% matrigel (Corning, New York, NY, USA) and were injected subcutaneously into the right flank of the randomized male BALB/c nude mice aged 4 to 6 weeks (seven mice per group) [9]. After tumor formation, tumor growth was monitored every 3–4 days, and the tumor volume was measured and calculated by the equation: volume = (Length x width^2) / 2. Finally, mice were sacrificed, and tumors were excised. Tumor weight was measured. Tumor tissues were collected for analysis.

For tumor metastasis assay, 5×10^5 CFPAC-1 cells with sh-circRTN4 or shSCR were resuspended in 1× PBS with 20% matrigel and were injected orthotopically to the head of the pancreas of randomized male BALB/c nude mice aged 4 to 6 weeks (four mice per group) [9]. The establishment and growth of tumor were monitored every 3–4 days. When the experiment reached the endpoint, mice were sacrificed. Tumors and organs were collected and examined for metastasis.

Protein stability assay
Analysis of protein stability was performed using cycloheximide (CHX) (Sigma) [13]. After circRTN4 knockdown in PANC-1 cells for 72h, cells were treated with 100μg/ml CHX for 2, 4 and 8h. The level of RAB11FIP1 and GAPDH at each time-point were analyzed by immunoblotting.

Immunohistochemical staining
Immunohistochemical staining was performed using Histostain-Plus IHC Kit, HRP, broad spectrum (Life Technologies, Carlsbad, CA, USA) [14]. The sections were probed with antibodies against Ki67 (rabbit; NB500–170 Novus Biologicals, Centennial, CO, USA; 1:100); Bcl-2 (rabbit; 04–436 Millipore; 1:100); HOXA13
purified by phenol:chloroform:isoamylalcohol (Invitrogen, TX, USA) overnight at 4 °C. RNA was
Proteintech) or TWF1 (mouse; sc-376,539 Santa Cruz
with antibody against RAB11FIP1 (rabbit; 16,778–1-AP
Briefly, cells were incubated magnetic beads labelled
(Millipore) according to the manufacturer’s protocol.
Briefly, cells were incubated magnetic beads labelled
with antibody against RAB11FIP1 (rabbit; 16,778–1-AP Proteintechn) or TWF1 (mouse; sc-376,539 Santa Cruz
Biotechnology, TX, USA) overnight at 4°C with rotation. The pulled-down proteins were identified
by Dionex Ultimate3000 nanoRSLC system coupled to
Thermo Fisher Orbitrap Fusion Tribid Lumos.

RNA immunoprecipitation
RNA immunoprecipitation was performed by Magna
RIP™ RNA-Binding Protein Immunoprecipitation Kit
(Millipore) according to the manufacturer’s protocol.
Briefly, cells were incubated magnetic beads labelled
with antibody against RAB11FIP1 (rabbit; 16,778–1-AP Proteintechn) or TWF1 (mouse; sc-376,539 Santa Cruz
Biotechnology, TX, USA) overnight at 4°C. RNA was
purified by phenol:chloroform:isoamylalcohol (Invitrogen). qRT-PCR was used to analyze the enrichment of
RNAs with target proteins.

Modelling of the circRTN4-RAB11FIP1 interaction
The 3-Dimensional structure of circRTN4 and RAB-
11FIP1 were modelled by the computational methods
3dRNA [15] and I-TASSER [16] respectively. Then, PRId-
tor [17] and HDOCK [18] with the default settings were
used to model the circRTN4-RAB11FIP1.

Analysis of publicly available datasets
Publicly available circRTN4 expression datasets in colo-
rectal cancer (CRC) (GSE126095) and laryngeal squa-
rous cell carcinoma (GSE12083) were obtained from
Gene Expression Omnibus (GEO) [19, 20]. CircRTN4
expression data in different cancer types were obtained
from MiOncoCirc [21].

Statistical analysis
Statistical analysis was performed by GraphPad Prism 7.
Two-tailed student’s t-test, chi square t-test and Pearson’s
correlation were used as appropriate. Data were shown in
mean ± SD. P-value of less than 0.05 was considered as
statistically significant.

Full methods were described in Supplementary
information.

Results
CircRTN4 was upregulated in PDAC
CircRNAs profiling in non-tumor HPDE cell and PDAC
PANC-1, SW1990 cells was performed to identify circR-
NAs that play critical roles in PDAC [9]. Among these
dysregulated circRNAs, circRTN4 was significantly
upregulated in PDAC cells (Fig. 1A). Also, we found that
circRTN4 was significantly upregulated in 60% of the
PDAC primary tumors (53 out of 88), while 18% of PDAC
patients showed downregulated circRTN4 (16 out of 88),
and 22% of PDAC patients showed unchanged circRTN4
(19 out of 88) (Fig. 1B). Furthermore, we correlated cir-
cRTN4 expression level with clinical characteristics. We
found that PDAC patients with liver metastasis had sig-
nificantly upregulated circRTN4 expression level in their
primary tumors (Fig. 1C), suggesting that the upregu-
lated circRTN4 in PDAC primary tumors may involve
in liver metastasis. Moreover, male PDAC patients and
patients aged 60 or above had further upregulated cir-
cRTN4 expression level (Table 1). In addition to PDAC,
we found that circRTN4 was frequently upregulated in multiple cancers, including colorectal cancer, laryn-
geal squamous cell carcinoma, head-neck squamous cell
 carcinoma, ovarian cancer, and kidney cancer (Supple-
mentary Fig. 1A-C) [19–21]. Collectively, these results
suggested that the upregulated circRTN4 play important
roles in PDAC.

We next characterized circRTN4 as a novel circRNA by
examining its physical circular structure. CircRTN4 was
formed by the back-splicing of exon 4 and exon 5 of RTN4
(Fig. 1D). Outward-facing divergent primers and inward-
facing convergent primers were designed to examine the
Circular structure of circRTN4 (Supplementary Fig. 2A).
Both the divergent and convergent primers amplified a
product of expected size using cDNA from PDAC cells,
whereas only the convergent primers amplified a prod-
uct using genomic DNA from PDAC cells (Supple-
mentary Fig. 2B). The presence of back-splicing junction was
further confirmed by Sanger sequencing (Supple-
mentary Fig. 2C). Moreover, we found that circRTN4 was resistant
to the digestion by RNase R which specifically degraded
linear RNAs but not the circRNAs (Supplementary
Fig. 2D). The reduced efficiency of reverse-transcription
by oligo-dT primers due to the lack of poly(A) tail also
demonstrated the circularity of circRTN4 (Supple-
mentary Fig. 2E). These results confirmed the actual existence
of circRTN4 and differentiated it from genomic rear-
rangement. In addition, the circular structure provided
enhanced stability to circRTN4 compared to its paren-
tal RTN4 mRNA. (Supplementary Fig. 2F). Also, coding
potential analysis suggested that circRTN4 was lack of
protein coding ability (Supplementary Table 3). Further-
more, cellular distribution of circRTN4 was examined

by measuring its expression in different cellular compartments. We found that the majority of circRTN4 was present in the cytoplasm of PDAC cells (Supplementary Fig. 2G). Collectively, we characterized the upregulated circRTN4 as a novel non-coding circRNA in PDAC.

**CircRTN4 promoted PDAC cell growth, migration and invasion in vitro**

To examine the functional roles of circRTN4 in PDAC, we used small interfering RNA (siRNA) which specifically targeted the back-splicing junction of circRTN4 without altering the expression of its parental RTN4 mRNA (Supplementary Fig. 3A and B). CircRTN4 knockdown significantly inhibited PDAC cell growth and clonogenic ability (Fig. 2A and B). The suppression in cell growth was due to cell cycle arrest in G0-G1 phase and the induction of apoptosis (Fig. 2C-E). PDAC cell migration and invasion were also restrained after circRTN4 knockdown (Fig. 2F and G). In addition, circRTN4 knockdown by the lentiviral sh-circRTN4 vector inhibited cell growth, migration,
and invasion in PDAC cells (Supplementary Fig. 3C-G). On the other hand, circRTN4 overexpression in non-tumor HPDE cells significantly promoted cell growth, clonogenic ability and cell invasion (Supplementary Fig. 4A-D). Collectively, our results demonstrated the importance of circRTN4 in promoting PDAC cell growth and invasion.

**CircRTN4 promoted PDAC tumor growth and liver metastasis in vivo**

To investigate the functional roles of circRTN4 in PDAC in vivo, mice xenograft model was generated by subcutaneous injection of CFPAC-1 sh-circRTN4 cells. CircRTN4 knockdown by shRNA significantly suppressed tumor growth (Fig. 3A-C). The decrease in cell proliferation marker Ki67 and anti-apoptotic protein Bcl-2 also indicated the inhibition of tumor growth by circRTN4 knockdown (Fig. 3D). Since in vitro studies revealed that circRTN4 promoted PDAC migration and invasion, we constructed a metastatic mice model through orthotopic injection of CFPAC-1 sh-circRTN4 cells to the pancreas. We found that circRTN4 knockdown inhibited PDAC metastasis to the liver (Fig. 3E). Collectively, our results suggested the functional importance of circRTN4 in promoting PDAC tumor growth and invasion.

**CircRTN4 promoted lncRNA HOTTIP expression by sponging miR-497-5p**

We next investigated the detailed mechanism of circRTN4-mediated PDAC progression. CircRNAs frequently function as miRNA sponges in regulating gene expression, we investigated whether circRTN4 also functioned as a miRNA sponge in promoting PDAC progression. Bioinformatics analysis by TargetScan revealed the potential miRNA binding sites on circRTN4 (Fig. 4A) [22]. To prove the circRTN4-miRNA interaction, luciferase assay using pmiR-circRTN4 reporter was performed after transfecting the miRNA mimics. Transfection of miR-497-5p mimics resulted in a reduction in luciferase activity (Fig. 4B). Conversely, mutating the miR-497-5p binding site of the pmiR-circRTN4 reporter could restore the luciferase activity (Fig. 4C). CircRTN4-miR-497-5p interaction was further validated by miRNA pull-down. Biotin-labelled miR-497-5p remarkably enriched circRTN4 in PANC-1 cells (Fig. 4D). These results suggested that circRTN4 interacted with miR-497-5p in PDAC cells. We next studied the functional roles of circRTN4-miR-497-5p interaction in PDAC. We demonstrated that circRTN4 knockdown increased the expression of miR-497-5p, whereas transfecting miR-497-5p mimics did not alter the expression of circRTN4 (Fig. 4E and F). Collectively, our results suggested that circRTN4 functioned as a sponge of miR-497-5p in PDAC cells.

**MiR-497-5p functions as a tumor suppressor in PDAC through targeting the oncogenic HOTTIP-HOXA13 pathway** [23, 24]. Since circRTN4 acts as a sponge for miR-497-5p, we hypothesized that circRTN4 regulates HOTTIP-HOXA13 pathway via sponging miR-497-5p in PDAC. CircRTN4 knockdown significantly inhibited the expression of HOTTIP and HOXA13 (Fig. 4G-I, Supplementary Fig. 5A). Moreover, circRTN4 overexpression

---

**Table 1** Correlations Between circRTN4 and Clinicopathologic Features in PDAC

| Clinicopathological Characteristics | Downregulated circRTN4 level | Unchanged circRTN4 | Upregulated circRTN4 | P-value |
|------------------------------------|-----------------------------|-------------------|---------------------|--------|
| Gender                             |                             |                   |                     |        |
| Female                             | 12 (34%)                    | 6 (17%)           | 17 (49%)            | 0.0085 |
| Male                               | 4 (7%)                      | 13 (25%)          | 36 (68%)            |        |
| Age, years                         |                             |                   |                     |        |
| < 60                               | 6 (24%)                     | 9 (36%)           | 10 (40%)            | 0.044  |
| ≥ 60                               | 10 (16%)                    | 10 (16%)          | 43 (68%)            |        |
| Tumor size, cm                     |                             |                   |                     |        |
| ≤ 4                                | 6 (12%)                     | 14 (27%)          | 32 (61%)            | 0.095  |
| > 4                                | 10 (28%)                    | 5 (14%)           | 21 (58%)            |        |
| Histological grade                 |                             |                   |                     |        |
| Poorly differentiated              | 2 (50%)                     | 1 (25%)           | 1 (25%)             | 0.053  |
| Moderately differentiated          | 8 (12%)                     | 15 (22%)          | 44 (66%)            |        |
| Well differentiated                | 4 (40%)                     | 1 (10%)           | 5 (50%)             |        |
| Tumor stage                        |                             |                   |                     |        |
| I-II                               | 13 (18%)                    | 18 (25%)          | 42 (57%)            | 0.393  |
| III-IV                             | 3 (21%)                     | 1 (7%)            | 10 (72%)            |        |
promoted the expression of HOTTIP and HOXA13 in HPDE cells (Supplementary Fig. 5B). In addition, transfection of miR-497-5p mimics rescued the effects of circRTN4 on the expression of HOTTIP and HOXA13 (Fig. 4I). Importantly, circRTN4 level was positively correlated to the upregulated HOTTIP level in PDAC primary tumors (Fig. 4K). These results suggested that circRTN4 functioned as a sponge of miR-497-5p to promote the expression of HOTTIP in PDAC.

**CircRTN4 stabilized RAB11FIP1 to promote EMT**

Although circRNAs-miRNAs interaction is the most reported roles of circRNAs in PDAC, many circRNAs are found to have much lower abundance than miRNAs. This suggests that circRNAs may have additional mechanisms in PDAC. Therefore, to further investigate the roles of circRTN4 in PDAC progression, we performed circRTN4-pull down to identify circRTN4-interacting proteins in PDAC cells. In vitro-transcribed circRTN4 functioned as a probe to pull down circRTN4-interacting proteins in PDAC cells. Mass-spectrometry analysis identified 99 proteins significantly enriched by circRTN4 (Fig. 5A). In addition, analysis using the STRING database [25] revealed 90 protein-protein interactions (PPI) for the circRTN4-interacting proteins (Supplemental Fig. 6A). Gene ontology analysis also suggested the critical roles of circRTN4-interacting proteins in multiple biological processes, including cadherin binding, cell adhesion and translation initiation (Supplemental Fig. 6B).

Particularly, we found that circRTN4 interacted with RAB11FIP1, which plays important roles in promoting cell migration and invasion in cancers [26–29]. CircRTN4-RAB11FIP1 interaction was further validated by RNA immunoprecipitation assay in PDAC cells (Fig. 5B). Bioinformatics analysis by PRIdictor also revealed the RAB11FIP1-binding site on circRTN4 (Supplementary Fig. 7) [17]. Mutating the RAB11FIP1-binding site on circRTN4 significantly inhibited the circRTN4-RAB11FIP1 interaction in PANC-1 cells (Fig. 5C). These confirmed that circRTN4 interacted with RAB11FIP1 in PDAC cells. We then investigated the functions of this interaction in PDAC. We found that knockdown of circRTN4 downregulated the RAB11FIP1 expression, without affecting its mRNA level (Fig. 5D and E). Importantly, circRTN4 knockdown decreased the stability of RAB11FIP1 in PDAC cells (Fig. 5F). We then further investigated the detailed mechanism on how circRTN4 regulated the stability of RAB11FIP1. Previous study showed that ubiquitination at the Lysine578 (Lys578) residue of RAB11FIP1 is required for its degradation [30]. Notably, we revealed the 3-Dimensional structure of circRTN4-RAB11FIP1 interaction by HDOCK [18], and found that circRTN4 blocked the ubiquitination site Lys578 on RAB11FIP1 (Fig. 5G). Also, circRTN4 knockdown in PDAC cells promoted the ubiquitination of RAB11FIP1 (Fig. 5H). Importantly, circRTN4 level was positively correlated to the RAB11FIP1 level in PDAC primary tumors (Fig. 5I). These suggested that circRTN4 interacted with RAB11FIP1 and enhanced the stability of RAB11FIP1 through inhibiting its ubiquitination in PDAC.

RAB11FIP1 plays important roles in promoting cancer migration and invasion through regulating the expression of EMT-related proteins (Supplementary Fig. 8A-C) [31, 32]. Therefore, we hypothesized that circRTN4 stabilizes RAB11FIP1 in regulating EMT in PDAC. We demonstrated that circRTN4 knockdown inhibited the expression of N-cadherin in PDAC cells and mice tumors (Fig. 6A and B). Also, we found the differential expression of EMT-related transcription factors in circRTN4-depleted PDAC cells. CircRTN4 knockdown inhibited expression of transcription factors Snail Family Transcriptional Repressor 2 (Slug), Snail Family Transcriptional Repressor 1 (Snai1), Twist Family BHLH Transcription Factor 1 (Twist) and Zinc Finger E-Box Binding Homeobox 1 (Zeb1) (Fig. 6C). In addition, knockdown of RAB11FIP1 rescued the effects of circRTN4 on the expression of Slug, Snai1, Twist and Zeb1 (Fig. 6D). Accordingly, we demonstrated that Slug, Snai1, Twist and Zeb1 were upregulated in PDAC primary tumors (Fig. 6E). A positive correlation was also found between Slug, Snai1, Twist, Zeb1 and circRTN4 expression (Fig. 6E). Taken together, our results suggested that circRTN4 stabilized RAB11FIP1 by blocking its ubiquitination to promote the expression of N-cadherin, Slug, Snai1, Twist and Zeb1 for EMT in PDAC.

**Discussion**

CircRNAs, as the novel member of non-coding RNA family, play vital roles in multiple cancers [6–8, 33]. With limited knowledge on the roles of circRNAs in PDAC, we
Fig. 2 (See legend on previous page.)
previously performed circRNA sequencing to identify differentially expressed circRNAs in PDAC cells [9]. One of the upregulated circRNAs, circRTN4, was examined in detail in the current study. RTN4 (also named as Nogo), which is a myelin-associated endoplasmic reticulum protein, is well-known for its function in the nervous system as an inhibitor of axon regeneration [34–36]. Moreover, differential expression of RTN4 is found in multiple cancers, which may function as a potential prognostic marker for gastric cancer [37–40]. Also, RTN4 promotes cancer progression by facilitating tumor proliferation and drug resistance [38, 39]. Notably, the exon 2 and 3 of RTN4 mRNA can be circularized to form a protein-coding circRNA: hsa_circ_0054598 in brain [41, 42]. Also, exosomal hsa_circ_0054598 may be used to treat osteoporosis [43]. In the current study, we demonstrated that another circRTN4, which is formed by the back-splicing of exon 4 and exon 5 of RTN4 mRNA, is significantly

Fig. 3 circRTN4 promotes PDAC tumor growth and liver metastasis. A-C CircRTN4 knockdown in CFPAC-1 cells inhibited tumor growth. (A) tumor volume and (B) mass of mice subcutaneous xenograft after knockdown of circRTN4 at day 34. (C) Hematoxylin and eosin staining of the subcutaneous xenograft tumors. D CircRTN4 knockdown in mice subcutaneous tumors decreased the cell proliferation marker Ki67 and anti-apoptotic protein Bcl-2 level, revealed by immunohistochemical staining. E CircRTN4 knockdown in mice orthotopic tumors inhibited liver metastasis. Representative images of liver metastasis were shown. Data represent mean ± SD from at least three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001).

Fig. 4 circRTN4 promotes HOTTIP expression by sponging miR-497-5p in PDAC. A Schematic diagram showing the putative binding sites of circRTN4 on miR-497-5p. B Reduction of luciferase activity of circRTN4-reporter in HEK293 cells co-transfected with miR-497-5p mimics with potential binding sites on circRTN4. C Mutating the miR-497-5p binding site on circRTN4-reporter restored the luciferase activity in HEK293 cells co-transfected with miR-497-5p mimics. D CircRTN4 was enriched by biotin-labelled miR-497-5p mimics in PANC-1 cells. E CircRTN4 knockdown increased the expression of miR-497-5p in PANC-1 cells. F Transfecting miR-497-5p mimics did not alter the expression of circRTN4 in PANC-1 cells. G-H (G) HOTTIP and (H) HOXA13 level were reduced after circRTN4 knockdown in PDAC cells. I CircRTN4 knockdown in mice subcutaneous tumors inhibited HOXA13 expression, revealed by immunohistochemical staining. J HOTTIP and HOXA13 expression were rescued in circRTN4-overexpressing HPDE cells after transfecting miR-497-5p mimics. K The upregulated HOTTIP were positively correlated with circRTN4 level in PDAC primary tumors. Data represent mean ± SD from at least three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001).
**Fig. 4** (See legend on previous page.)

**A**

```
circRTN4 (5' ... 3') UGUUGGGUGC CAGCCCAUUCUCUGCUCU
hsa-miR-497-5p (3' ... 5') GUUUGGGUGUC ACGACGAC

circRTN4-mut (5' ... 3') UGUUGGGUGCAGCCUAUUCU ACGACU
```

**B**

![Relative luciferase activity graph]

**C**

Relative luciferase activity for Luc-circRTN4 and Luc-circRTN4-mut.

**D**

Relative circRTN4 enrichment for miRNC and miR-497-5p.

**E**

Relative miR-497-5p level for si-miRNC and si-circRTN4.

**F**

Relative expression level for circRTN4 and HOTTIP.

**G**

Relative expression level for HOTTIP and HOTTIP si-circRTN4 in PANC-1 and CFPAC-1.

**H**

Western blot for HOXA13 and GAPDH in PANC-1 and CFPAC-1.

**I**

IHC score for HOXA13 and sh-circRTN4.

**J**

Relative expression level for HOTTIP, HOXA13, and Ctrl + miRNC, circRTN4 + miRNC, circRTN4 + mir-497-5p.

**K**

| circRTN4 | Up | Down/Unchanged |
|----------|----|----------------|
|          |    |                |

| HOTTIP   | Up | Down/Unchanged |
|----------|----|----------------|
|          |    |                |

```

*p<0.001

n=88

p=0.0274
```
circRTN4 stabilizes RAB11FIP1 by preventing its ubiquitination and degradation. **A** Heat-map showing 99 circRTN4-interacting proteins in PDAC. Biotin-labelled circRTN4, RTN4 mRNA, circGFP were used to pull down circRTN4-interacting proteins. Mass spectrometry analysis was performed to identify the interacting proteins. **B** CircRTN4 interacted with RAB11FIP1 in PDAC cells, as revealed by RIP assay. **C** Bioinformatics analysis by PIDictor revealed the RAB11FIP1-binding site (The seed region of interaction was in red) on circRTN4. Mutating RAB11FIP1-binding site on circRTN4 (The mutated seed region of interaction was in green) inhibited circRTN4-RAB11FIP1 interaction in PANC-1 cells, as revealed by circRNA pulldown assay. **D** CircRTN4 knockdown inhibited RAB11FIP1 expression in mice xenograft. **E** CircRTN4 knockdown did not affect RAB11FIP1 mRNA level in PDAC cells. **F** CircRTN4 knockdown decreased the stability of RAB11FIP1 after inhibition of protein synthesis by cycloheximide in PANC-1 cells. **G** 3-Dimensional structure of the circRTN4-RAB11FIP1 interaction revealed that circRTN4 blocked the ubiquitination site Lys578 of RAB11FIP1. **H** Immunoprecipitation with anti-RAB11FIP1 antibody in PANC-1 cells after circRTN4 knockdown, followed by immunoblotting analysis with anti-ubiquitin or anti-RAB11FIP1 antibody. CircRTN4 knockdown increased ubiquitination of RAB11FIP1. **I** RAB11FIP1 expression were upregulated in PDAC primary tumors and was positively correlated with circRTN4 level. Data represent mean ± SD from at least three independent experiments (*p<0.05; **p<0.01; ***p<0.001)
upregulated in PDAC cells and primary tumors. Also, PDAC patients with liver metastasis have high circRTN4 level in their primary tumors. Furthermore, the biological roles of circRTN4 in promoting PDAC cell growth and liver metastasis are explored in knockdown and overexpression experiments.

CircRNAs can reportedly interact with and sponge miRNAs in regulating gene expression in PDAC. circRNA_100782 promotes PDAC tumor growth by sponging tumor suppressor miR-124 [44]. hsa_circRNA_0007334 inhibits miR-144-3p and miR-577 to upregulate collagen type I alpha 1 chain and matrix metallopeptidase 7 [45]. ciRS-7 and circPDE8A promote PDAC cell growth and invasion by targeting miR-7 and miR-338 respectively [46, 47]. CircRHOT1 promotes PDAC cell invasion by sponging miR-26b, miR-125a, miR-330 and miR-382 [48]. Consistently, we demonstrated that circRTN4 sponged tumor-suppressive miR-497-5p in PDAC. Notably, we previously reported that miR-497-5p inhibited PDAC progression through suppressing the oncogenic HOTTIP-HOXA13.

Fig. 6  circRTN4 stabilizes RAB11FIP1 to promote EMT in PDAC. A N-cadherin expression was inhibited after circRTN4 knockdown in PANC-1 cells. B CircRTN4 knockdown in mice subcutaneous tumors inhibited N-cadherin expression. C Expression of EMT markers Slug, Snai1, Twist and Zeb1 were reduced after circRTN4 knockdown in PDAC cells. D Expression of Slug, Sna1, Twist and Zeb1 in circRTN4-overexpressing HPDE cells were rescued after RAB11FIP1 knockdown. E Slug, Sna1, Twist and Zeb1 expression were upregulated in PDAC primary tumors and were positively correlated with circRTN4 level. Data represent mean ± SD from at least three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001)
pathway [24]. In current study, we demonstrated that circRTN4 is the regulator of HOTTIP, which is one of the well-characterized IncRNA. HOTTIP complexed with MLL1 and WDR5 to promote gene-activating H3K4 trimethylation at the gene promoter [49, 50]. In many cancer types, HOTTIP is frequently upregulated and plays critical roles in promoting cancer progression [51–54]. Upregulation of HOTTIP promotes cancer growth and invasion in colorectal cancer [51]. Also, HOTTIP promotes tumor growth and metastasis through regulating HOXA genes in hepatocellular carcinoma [54]. We demonstrated that the upregulated HOTTIP promoted PDAC cell growth and invasion under the negative regulation by miR-497-5p [24]. In current study, we identified a novel circRTN4-miR-497-5p-HOTTIP pathway in PDAC. We demonstrated that circRTN4 promotes HOTTIP expression through inhibiting miR-497-5p. This demonstrated a novel role of circRNA in regulating the expression of IncRNA through circRNA-miRNA-lncRNA pathway in cancer.

Functioning as miRNAs sponges is the first identified role of circRNAs [55]. Many studies have also demonstrated the importance of miRNAs sponges in cancer development. Notably, there is growing evidence to show that circRNAs regulate gene expression through circRNA-protein interactions, suggesting circRNAs may have more than one mode of action. circADD3 complexes with CDK1 to protect EZH2 from degradation [31]. circCTNNB1 interacts with DDX3 and YY1 to promote gene expression [56]. circFOXK3 binds and inhibits the activities of CDK2 and p21 [57]. We also demonstrated that circFOXK2 complexes with YBX1 and hnRNPK in promoting the expression of oncogenic proteins NUF2 and PDXK in PDAC [9]. Herein, circRNA pull-down and mass spectrometry were performed to identify circRTN4 binding proteins. We identified 99 circRTN4-interacting proteins that are involved in several biological processes, including cell adhesion and cadherin binding. We demonstrated that circRTN4 interacts with RAB11FIP1 in PDAC cells. Most importantly, our data showed that circRTN4 stabilizes RAB11FIP1 by preventing its ubiquitination. RAB11FIP1 is a member of GTP-bound Rab11 effectors, regulated cell polarity through participating in the vesicle trafficking system [58–60]. Several studies reported that the upregulation of RAB11FIP1 and RAB11FIP2 and their interacting partner RAB11a promotes cancer migration and invasion [26–29]. RAB11FIP1 protects integrins from degradation, regulates cadherin recycling and promotes the expression of EMT-related transcription factors [27, 29, 31, 32, 61, 62]. In this study, we found that circRTN4 promotes EMT via RAB11FIP1-mediated upregulation of N-cadherin, Slug, Snai1, Twist and Zeb1 in PDAC. These may suggest the importance of circRTN4 in promoting cancer metastasis by EMT in PDAC.

Conclusion
In summary, our study emphasizes the significance of circRTN4 in PDAC progression. CircRTN4 is ectopically expressed in many cancers, including PDAC. Overexpression and knockdown studies indicated the upregulated circRTN4 promotes PDAC cell growth and liver metastasis. Mechanistically, circRTN4 promotes expression of oncogenic HOTTIP by sponging miR-497-5p. This reveals a novel circRNA-miRNA-lncRNA pathway in promoting PDAC progression. Furthermore, we provide a new perspective on the tumorigenic ability of circRTN4 through stabilizing RAB11FIP1 by blocking its ubiquitination to enhance the expression of EMT markers in PDAC. This highlights the potential of circRTN4 as a novel biomarker and a potential therapeutic target for PDAC.

Abbreviations
- circRNA: Circular RNA; Ctrl: Control; DMEM: Dulbecco’s modified Eagle’s medium; EMT: Epithelial-Mesenchymal Transition; FBS: Fetal bovine serum; FFPE: Formalin-fixed, paraffin-embedded; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; HOTTIP: HOXA Distal Transcript Antisense RNA; HOXA13: Homeobox A13; IncRNA: Long non-coding RNA; miRNA: Micro RNA; MTT: 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; NC: Negative control; PARP: Poly(ADP-Ribose) Polymerase 1; PBS: Phosphate buffered saline; PCR: Polymerase chain reaction; PDAC: Pancreatic ductal adenocarcinoma; PPI: Protein-protein interaction; qRT-PCR: Quantitative reverse transcription PCR; RIP: RNA immunoprecipitation; RAB11FIP1: RAB11 Family Interacting Protein 1; RTN4: Reticulon 4; siRNA: Small interfering RNA; Slug: Snail Family Transcriptional Repressor 1; Snai1: Snail Family Transcriptional Repressor 1; Twist: Twist Family BHLH Transcription Factor 1; Zeb1: Zinc Finger E-Box Binding Homeobox 1.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12935-021-01481-w.

Additional file 1: Supplementary methods. Supp Figure 1. circRTN4 is upregulated in cancer. Supp Figure 2. Characterization of circRTN4 in PDAC cells. Supp Figure 3. circRTN4 promotes PDAC cell growth, migration and invasion. Supp Figure 4. circRTN4 promotes PDAC cell growth and invasion. Supp Figure 5. circRTN4 promotes the expression of oncogenic HOTTIP-HOXA13 pathway in PDAC. Supp Figure 6. Identification of circRTN4-interacting proteins in PDAC. Supp Figure 7. Prediction of circRTN4-RAB11FIP1 interaction. Supp Figure 8. RAB11FIP1 promotes the expressions of N-cadherin and EMT-related transcription factors in PDAC. Supp Table 1. siRNA sequences for gene knockdown and miRNA mimic sequences. Supp Table 2. Oligos used in this study. Supp Table 3. Coding potential analysis of circRTN4 by Coding Potential Assessment Tool.

Acknowledgments
We greatly acknowledge the support of The Proteomics and Metabolomics Core Facility, Li Ka Shing Faculty of Medicine, The University of Hong Kong in performing the mass spectrometry.
Authors’ contributions
CHW designed and performed most of the experiments and drafted the manuscript. UKL and FKCF assisted to obtain data. JHMT and KFT provided some research materials. CZ and SLC assisted to preparation of the experiments. YC was the PI of the grant, overlooked the whole progress and revised the manuscript. The authors read and approved the final manuscript.

Funding
The work described in this paper was supported by grants from the General Research Fund, Research Grants Council of Hong Kong Special Administrative Region, China (#4171217, 14120618 and 14120419), National Natural Science Foundation of China (81672323) to YC.

Availability of data and materials
CircRNA sequencing data are available in the NCBI Gene Expression Omnibus under accession number GSE135731. The GEO accession token for reviewer CircRNA sequencing data are available in the NCBI Gene Expression Omnibus.

Foundation of China (81672323) to YC.

Region, China (14171217, 14120618 and 14120419), National Natural Science Foundation of China (81672323) to YC.


gdnissignonloyx. Mass spectrometry data of circRNA pull‑down are available via ProteomeXchange with identifier PXD015048. The ProteomeXchange reviewer username and password were reviewer30182@ebi.ac.uk; 494HJCaH.

Availability of data and materials
CircRNA sequencing data are available in the NCBI Gene Expression Omnibus under accession number GSE135731. The GEO accession token for reviewer CircRNA sequencing data are available in the NCBI Gene Expression Omnibus.


den analyzed and the Ethical Committee. Clinical samples were collected from patients after written informed consent was obtained. Animal handling and experimental procedures were approved by the Animal Experimental Ethics Committee.

Declarations
Ethics approval and consent to participate
The study was performed with the approval of the Joint CUHK‑NTEC Clinical Research Ethics Committee. Clinical samples were collected from patients after written informed consent was obtained. Animal handling and experimental procedures were approved by the Animal Experimental Ethics Committee of the institute.

Consent for publication
All authors have agreed to publish this manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. 2Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. 3Digestive Medicine Center, The Seventh Affiliated Hospital of Sun Yat‑Sen University, Shenzhen 518107, Guangdong, China. 4Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. 5Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen 518087, China.

Received: 7 November 2021   Accepted: 13 December 2021
Published online: 04 January 2022

References
1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Silvestris N, et al. Clinical practice guidelines for diagnosis, treatment and follow‑up of exocrine pancreatic ductal adenocarcinoma: evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM). Cancers (Basel). 2020;12:1681.
3. Furuse J, Shibahara J, Sugiyama M. Development of chemotherapy and follow‑up of exocrine pancreatic ductal adenocarcinoma: evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM). Cancers (Basel). 2020;12:1681.
4. Siegel RL, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
5. Liang Y, et al. circDMC4 suppresses tumor progression and attenuates doxorubicin resistance by regulating miR‑548p/PDLD axis in breast cancer. Oncogene. 2019;38:6850–66.
6. Wang L, et al. Circular RNA circHOT1 promotes hepatocellular carcinoma progression by inactivation of NR2F6 expression. Mol Oncol. 2019;13:119.
7. Zhang Z, et al. Circular RNA ATXN7 promotes the development of gastric cancer through sponging miR‑4319 and regulating ENTPD4. Cancer Cell Int. 2020;20:25.
8. Kristensen LS, et al. The biogenesis, biology and characterization of circuluar RNAs. Nat Rev Genet. 2019;20:675–91.
9. Wong CH, et al. CircFOXK2 promotes tumor growth and metastasis of pancreatic ductal adenocarcinoma via Complexing with RNA binding proteins and sponging MiR‑942. Cancer Res. 2020;80:2138–49.
10. Ouyang H, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000;157:1623–31.
11. Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production. Genes Dev. 2014;28:2233–47.
12. Xu F, et al. Genome‑wide screening and functional analysis identifies tumor suppressor long noncoding RNAs epigenetically silenced in hepatocellular carcinoma. Cancer Res. 2019;79:1305–17.
13. Kao SH, et al. Analysis of protein stability by the Cytoheximide chase assay. Bio Protoc. 2015;5:e1374.
14. Zhu YX, et al. LLGL1 regulates gemcitabine resistance by modulating the ERK‑SP1‑OSMR pathway in pancreatic ductal adenocarcinoma. Cell Mol Gastroenterol Hepatol. 2020;10:1–18.
15. Wang J, et al. 3DRNA v2.0: an updated web server for RNA 3D structure prediction. Int J Mol Sci. 2019;20:4116.
16. Yang J, Zhang Y. TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 2015;43:W174–81.
17. Tuvshinjargal N, et al. PRLtector: protein‑RNA interaction predictor. Bioinformatics. 2016;32:33–40.
18. Chen Z, et al. Hsa‑cric_101555 functions as a competing endogenous RNA of miR‑597‑5p to promote colorectal cancer progression. Oncogene. 2019;38:6017–34.
19. Gao W, et al. Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous cell carcinoma by impairing PLK1‑AKT axis‑mediated glycolysis. Cell Death Dis. 2020;11:919.
20. Vo JN, et al. The landscape of circular RNA in cancer. Cell. 2019;176:869–881.e13.
21. Agarwal V, et al. Predicting effective microRNA target sites in mammalian miRNAs. Elife. 2015;4:e05005.
22. Xu J, et al. MiR‑497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget. 2014;5:6983–93.
23. Wong CH, et al. Ectopic HOTTIP expression induces non‑canonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. Cancer Lett. 2020;477:1–9.
24. Szklarczyk D, et al. STRING v11: protein‑protein association networks with increased coverage, supporting functional discovery in genome‑wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.
25. Choe SR, et al. RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin. Exp Mol Med. 2018;50:52.
26. Rainero E, et al. Diacylglycerol kinase α controls RCP‑dependent integrin trafficking to promote invasive migration. J Cell Biol. 2012;196:277–95.
27. Zhang J, et al. RCP is a human breast cancer‑promoting gene with RAS‑activating function. J Clin Invest. 2009;119:2171–83.
28. Caswell PT, et al. Rab‑coupling protein coordinates recycling of alpha‑Spectrin integrin and EGFRI to promote cell migration in 3D microenvironments. J Cell Biol. 2008;173:143–55.
29. Sharmar K, et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser Thr‑based signaling. Cell Rep. 2014;8:1583–94.
30. Hwang MH, et al. RCP induces slug expression and cancer cell invasion by stabilizing B1 integrin. Oncogene. 2017;36:1102–11.
31. Kim JY, et al. Zeb1 for RCP‑induced oral cancer cell invasion and its suppression by resveratrol. Exp Mol Med. 2020;52:1152–63.
32. Kim JY, et al. The landscape of circular RNA in cancer. Cell. 2019;176:869–881.e13.
33. Zhou J, et al. PRIdictor: protein‑RNA interaction predictor. Bioinformatics. 2016;32:33–40.
34. Zhao Y, et al. TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 2015;43:W174–81.
35. Chiurchiù V, Maccarrone M, Orlacchio A. The role of reticulons in neurodegenerative diseases. Neurochem Res. 2015;40:1767–85.
37. Chi C, et al. RTN4/Nogo is an independent prognostic marker for gastric cancer: preliminary results. Eur Rev Med Pharmacol Sci. 2015;19:241–6.
38. Zhu B, et al. Knockout of the Nogo-8 gene attenuates tumor growth and metastasis in hepatocellular carcinoma. Neoplasia. 2017;19:583–93.
39. Pathak GP, et al. RTN4 knockout Dysregulates the AKT pathway, destabilizes the cytoskeleton, and enhances paclitaxel-induced cytotoxicity in cancers. Mol Ther. 2018;26:2019–33.
40. Jin SG, et al. Nogo-a inhibits the migration and invasion of human malignant glioma U87MG cells. Oncol Rep. 2016;35:3395–402.
41. Rybak-Wolf A, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58:870–85.
42. Mo D, et al. A universal approach to investigate circRNA protein coding function. Sci Rep. 2019;9:11684.
43. Cao G, et al. Exosomes derived from circRNA Rtn4-modified BMSCs attenuate TNF-α-induced cytotoxicity and apoptosis in murine MC3T3-E1 cells by sponging miR-146a. Biosci Rep. 2020;40:B9R20193436.
44. Chen G, et al. CircRNA_100782 regulates pancreatic carcinoma proliferation through the IL6-STAT3 pathway. Onco Targets Ther. 2017;10:5783–94.
45. Yang J, et al. Circular RNA hsa_circRNA_0007334 is predicted to promote MMP7 and COL1A1 expression by functioning as a miRNA sponge in pancreatic ductal adenocarcinoma. J Oncol. 2019;7630894.
46. Li Z, et al. Tumor-released exosomal circular P2A PDE6A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Lett. 2018;432:237–50.
47. Liu L, et al. Circular RNA cirs-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway. Hepatobiliary Pancreat Dis Int. 2019;18:580–6.
48. Qu S, et al. Circular RNA cir-RHOT1 is upregulated and promotes cell proliferation and invasion in pancreatic cancer. Epigenomics. 2019;11:53–63.
49. Guenther MG, et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A. 2005;102:8603–8.
50. Wang KC, et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature. 2011;472:120–4.
51. Liu T, et al. The long non-coding RNA HOTTIP is highly expressed in colorectal cancer and enhances cell proliferation and invasion. Mol Ther Nucleic Acids. 2020;19:612–8.
52. Malek R, et al. TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis. Cancer Res. 2017;77:3181–93.
53. Sang Y, et al. Up-regulation of long non-coding HOTTIP functions as an oncoogene by regulating HOXA13 in non-small cell lung cancer. Am J Transl Res. 2016;8:2022–32.
54. Tsang FH, et al. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. Liver Int. 2015;35:597–606.
55. Memczak S, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
56. Yang F, et al. Cis-acting circ-CTNNB1 promotes β-catenin signaling and cancer progression via DDX3-mediated transactivation of YY1. Cancer Res. 2018;78:557–71.
57. Du WW, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44:2846–58.
58. Goldenring JR. A central role for vesicle trafficking in epithelial neoplasia: intracellular highways to carcinogenesis. Nat Rev Cancer. 2013;13:813–20.
59. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–69.
60. Schafer JC, et al. Rab11-FIP1A regulates early trafficking into the recycling endosomes. Exp Cell Res. 2016;340:259–73.
61. Chung YC, et al. Rab11 regulates E-cadherin expression and induces cell transformation in colorectal carcinoma. BMC Cancer. 2014;14:587.
62. McRae R, et al. Rab11-FIP1 phosphorylation by MARK2 regulates polarity in MDCK cells. Cell. Logist. 2017;7:e1271498.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.